Histologic classification of glomerular diseases: Clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification

Kidney International

Volumn 85, Issue 4, 2014, Pages 779-793

  Haas, Mark ^a   Rastaldi, Maria P ^b   Fervenza, Fernando C ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Department of Health Sciences Research   (United States)

Author keywords

ANCA vasculitis; IgA nephropathy; Lupus nephritis; Renal biopsy

Indexed keywords

ANCA ASSOCIATED CRESCENTIC GLOMERULONEPHRITIS; ANCA ASSOCIATED VASCULITIS; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; END STAGE RENAL DISEASE; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INTERNATIONAL SOCIETY OF NEPHROLOGY; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; OUTCOME ASSESSMENT; OXFORD CLASSIFICATION; PRIORITY JOURNAL; PROGNOSIS; RENAL PATHOLOGY SOCIETY; REPEAT PROCEDURE; REVIEW; SCORING SYSTEM; VALIDATION PROCESS; VALIDATION STUDY; BIOPSY; CLASSIFICATION; GLOMERULUS; NEPHROLOGY; PATHOLOGY; STANDARDS; TRENDS; CHRONICITY; DISEASE ASSOCIATION; DISEASE SEVERITY; RENOVASCULAR DISEASE; REPRODUCIBILITY;

BIOPSY; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; NEPHROLOGY; PROGNOSIS; VALIDATION STUDIES AS TOPIC;

EID: 84897954330     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.375     Document Type: Review

References (94)

1. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422.
2. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
3. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria-An addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
4. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
5. Petri M, Orbai AM, Alarcón GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
6. Hahn BH, McMahon MA, Wilkinson A et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
7. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012; 139-274.
8. Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782.
9. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of lupus nephritis revisited. Kidney Int 2004; 65: 521-530.
10. Markowitz GS, D'Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens 2009; 18: 220-225.
11. Furness PN, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-A UK-wide study. Am J SurgPathol 2006; 30: 1030-1035.
12. Yokoyama H, Wada T, Hara A et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66: 2382-2388.
13. Grootscholten C, Bajema IM, Florquin S et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant 2008; 23: 223-230.
14. Najafi CC, Korbet SM, Lewis EJ et al. Significance of histologic patterns of glomerular injury upon long-Term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163.
15. Mittal B, Hurwitz S, Rennke H et al. New subcategories of class IV lupus nephritis: Are there clinical, histologic, and outcome differences?. Am J Kidney Dis 2004; 44: 1050-1059.
16. Hill GS, Delahousse M, Nochy D et al. Class IV-S versus class IV-G lupus nephritis: Clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005; 68: 2288-2297.
17. Yu F, Tan Y, Wu LH et al. Class IV-G and IV-S lupus nephritis in Chinese patients: A large cohort study from a single center. Lupus 2009; 18: 1073-1081.
18. Kojo S, Sada KE, Kobayashi M et al. Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. J Rheumatol 2009; 36: 2218-2223.
19. Hiramatsu N, Kuroiwa T, Ikeuchi H et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford) 2008; 47: 702-707.
20. Haring CM, Rietveld A, van den Brand JA et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol 2012; 23: 149-154.
21. Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008; 23: 1298-1306.
22. Austin HA 3rd, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391.
23. Charney DA, Nassar G, Truong L et al. Pauci-immune proliferative and necrotizing glomerulonephritis with thrombotic microangiopathy in patients with systemic lupus erythematosus and lupus-like syndrome. Am J Kidney Dis 2009; 35: 1193-1206.
24. D'Agati VD. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren's syndrome, and rheumatoid arthritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds). Heptinstall's Pathology of the Kidney, 6th edn. Lippincott Williams & Wilkins: Philadelphia, 2007, pp 517-612.
25. Schwartz MM, Lan SP, Bonsib SM et al. Clinical outcome of three distinct histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989; 13: 273-283.
26. Austin HA III, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
27. Contreras G, Pardo V, Cely C et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14: 890-895.
28. Wu LH, Yu F, Tan Y et al. Inclusion of renalvascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83: 715-723.
29. Conlon PJ, Fischer CA, Levesque MC et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996; 46: 170-175.
30. Schwartz MM, Lan SP, Bernstein J et al. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1993; 21: 374-377.
31. Hill GS, Delahousse M, Nochy D et al. Predictive power of the second renal biopsy in lupus nephritis: Significance of macrophages. Kidney Int 2001; 59: 304-316.
32. Yu F, Wu LH, Tan Y et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010; 77: 820-829.
33. Hsieh C, Chang A, Brandt D et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 2011; 63: 865-874.
34. Barber C, Herzenberg A, Aghdassi E et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 2012; 7: 757-764.
35. Song D, Li-H Wu, Wang F-M et al. The spectrum of thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013; 15: R12.
36. Font J, Torras A, Cervera R et al. Silent renal disease in systemic lupus erythematosus. Clin Nephrol 1987; 27: 283-288.
37. Wakasugi D, Gono T, Kawaguchi Y et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: An analysis of predictive measures. J Rheumatol 2012; 39: 79-85.
38. Wada Y, Ito S, Ueno M et al. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004; 98: C105-c111.
39. Daleboudt GM, Bajema IM, Goemaere NN et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009; 24: 3712-3717.
40. Appel GB, Contreras G, Dooley MA et al. Mycopenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
41. Chan TM, Tse KC, Tang CS et al. Long-Term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
42. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclosposphamide for lupus nephritis. New Engl J Med 2005; 353: 2219-2228.
43. Tourna Z, Gladman DD, Urowitz MB et al. Mycophenolate mofetil for induction treatment of lupus nephritis: A systematic review and metaanalysis. J Rheumatol 2011; 38: 69-78.
44. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. New Engl J Med 2011; 365: 1886-1895.
45. Kraft SW, Schwartz MM, Korbet SM et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005; 16: 175-179.
46. Salvatore SP, Barisoni LMC, Herzenberg AM et al. Collapsing glomulopathy in 19 patients with systemic lupus erythematosus or lupuslike disease. Clin J Am Soc Nephrol 2012; 7: 914-925.
47. Berger J. IgA glomerular deposits in renal disease. Transplant Proc 1969; 1: 939-944.
48. Ibels LS, Gyory AZ. IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine 1994; 73: 79-102.
49. Lee SM, Rao VM, Franklin WA et al. IgA nephropathy: Morphologic predictors of progressive renal disease. Hum Pathol 1982; 13: 314-322.
50. Haas M. Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-842.
51. Radford MG, Donadio JV, Bergstralh EJ et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207.
52. Lee HS, Koh HI, Lee HB et al. IgA nephropathy in Korea: A morphological and clinical study. Clin Nephrol 1987; 27: 131-140.
53. Alamartine E, Sabatier JC, Berthoux EC. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: Value of quantitative scoring and approach to final prognosis. Clin Nephrol 1990; 34: 45-51.
54. Frimat L, Briancon S, Hestin D et al. IgA nephropathy: Prognostic classification of end-stage renal failure. Nephrol Dial Transplant 1997; 12: 2569-2575.
55. Daniel L, Saingra Y, Giorgi R et al. Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 2000; 35: 13-20.
56. D'Amico G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-237.
57. Lv J, Zhang H, Zhou Y et al. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: A long-Term follow up of 204 cases in China. Nephrology (Carlton) 2008; 13: 242-246.
58. Manno C, Stippoli GFM, D'Altri C et al. A novel simpler histological classification for renal survival in IgA nephropathy: A retrospective study. Am J Kidney Dis 2007; 49: 763-775.
59. Lai FM-M, Szeto CC, Choi PCL et al. Primary IgA nephropathy with low histologic grade and disease progression: Is there a ''point of no return''?. Am J Kidney Dis 2002; 39: 401-406.
60. Bartosik LP, Lajoie G, Sugar L et al. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735.
61. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
62. Roberts IS, Cook HT, Troyanov S et al. The Oxford Classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556.
63. Hotta OA, Furuta T, Chiba S et al. Regression of IgA nephropathy: A repeat biopsy study. Am J Kidney Dis 2002; 39: 493-502.
64. Mengel M, Reeve J, Bunnag S et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9: 1859-1867.
65. Mannon RB, Matas AJ, Grande J et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 2010; 10: 2066-2073.
66. Bellur SS, Troyanov S, Cook HT et al. Immunostaining findings in IgA nephropathy: Correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant 2011; 26: 2533-2536.
67. Andreoli SP, Yum MN, Bergstein JM. IgA nephropathy in children: Significance of glomerular basement membrane deposition of IgA. Am J Nephrol 1986; 6: 28-33.
68. Lee HS, Choi Y, Lee JS et al. Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. Kidney Int 1989; 35: 880-886.
69. Coppo R, Troyanov S, Camilla R et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 2010; 77: 921-927.
70. Herzenberg AM, Fogo AB, Reich HN et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011; 80: 310-317.
71. Alamartine E, Sauron C, Laurent B et al. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 2011; 6: 2384-2388.
72. El Karoui K, Hill GS, Karras A et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79: 643-654.
73. Lee H, Yi SH, Seo MS et al. Validation of the Oxford classification of IgA nephropathy: A single-center study in Korean adults. Korean J Intern Med 2012; 27: 293-300.
74. Kang SH, Choi SR, Park HS et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant 2012; 27: 252-258.
75. Katafuchi R, Ninomiya T, Nagata M et al. Validation study of oxford classification of IgA nephropathy: The significance of extracapillary proliferation. Clin J Am Soc Nephrol 2011; 6: 2806-2813.
76. Zeng CH, Le W, Ni Z et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis 2012; 60: 812-820.
77. Shi SF, Wang SX, Jiang L et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: Validation of the oxford classification. Clin J Am Soc Nephrol 2011; 6: 2175-2184.
78. Halling SE, Soderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 2012; 27: 715-722.
79. Shima Y, Nakanishi K, Hama T et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol 2012; 27: 783-792.
80. Le W, Zeng CH, Liu Z et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol 2012; 13: 158.
81. Yau T, Korbet SM, Schwartz MM et al. The Oxford classification of IgA nephropathy: A retrospective analysis. Am J Nephrol 2011; 34: 435-444.
82. El Karoui K, Hill GS, Karras A et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 137-148.
83. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
84. Troyanov S, Fervenza FC. Validating the oxford classification of IgA nephropathy. Clin J Am Soc Nephrol 2011; 6: 2335-2336.
85. Jennette JC, Thomas DB. Pauci-immune and antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis and vasculitis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds). Heptinstall's Pathology of the Kidney, 6th edn. Lippincott Williams & Wilkins: Philadelphia, 2007, pp 643-700.
86. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-Associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628-1636.
87. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al. Clinical and histologic determinants of renal outcome in ANCA-Associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17: 2264-2274.
88. Hilhorst M, Wilde B, van Paassen P et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-Associated glomerulonephritis: A 30-year follow-up study. Nephrol Dial Transplant 2013; 28: 373-379.
89. Chang DY, Wu LH, Liu G et al. Re-evaluation of the histopathologic classification of ANCA-Associated glomerulonephritis: A study of 121 patients in a single center. Nephrol Dial Transplant 2012; 27: 2343-2349.
90. Muso E, Endo T, Itabashi M et al. Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-Anti-neutrophil cytoplasmic autoantibody-Associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol; e-pub ahead of print 21 December 2012.
91. Pepper RJ, Chanouzas D, Tarzi R et al. Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-Associated vasculitis. Clin J Am Soc Nephrol 2013; 8: 219-224.
92. Berden AE, Jones RB, Erasmus DD et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-mediated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012; 23: 313-321.
93. D'Agati VD, Fogo AB, Bruijn JA et al. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 2004; 43: 368-382.
94. Cohen Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21: 556-563.